Rapamycin (Longevity Context) — Research Profile

Rapamycin has a well-characterized side effect profile from decades of transplant medicine use, but longevity protocols use much lower, intermittent doses. Weekly dosing of 3-6mg appears to minimize immunosuppression while retaining mTOR inhibition benefits. However, long-term safety data for off-label longevity use is limited. This must be used under expert medical supervision with regular blood monitoring for lipids, glucose, and immune function.

Transplant patients take rapamycin daily at 2-5mg to continuously suppress immune function and prevent organ rejection. Longevity protocols use intermittent dosing — typically 3-6mg once weekly — which allows mTOR to reactivate between doses. This pulsed approach appears to provide anti-aging benefits (autophagy, reduced senescence) while minimizing immunosuppression. Mannick et al. showed this intermittent approach actually enhanced immune function.

No. Rapamycin (sirolimus) is a prescription medication that requires a doctor's prescription. It is not available as an over-the-counter supplement. Some longevity-focused physicians prescribe it off-label based on the research, but it requires regular blood monitoring. Never attempt to self-source or self-medicate with rapamycin — the drug interactions and side effects require professional management.

Oral sirolimus, as a tablet or oral solution, is the only form used in humans, and longevity protocols take it intermittently by mouth rather than daily. Commercial Rapamune and compounded rapamycin are not interchangeable: compounded product delivered about one-third the blood level at 24 hours in the PEARL trial, so the same milligram number is not the same exposure. There is no inhaled or oral "anti-aging" formulation validated for this use.

The strongest evidence is in animals: rapamycin fed to genetically heterogeneous mice starting late in life extended both median and maximal lifespan, with the age at 90% mortality rising about 14% in females and 9% in males. In humans the data are far more limited: the rapamycin analog everolimus improved elderly influenza-vaccine antibody responses by roughly 20%, and the PEARL trial found improved lean tissue mass and reduced self-reported pain in women on 10 mg weekly but no change in its primary visceral-fat endpoint. No human trial has shown that rapamycin extends lifespan.

Longevity use is not a daily-dose question; off-label protocols and trials use intermittent weekly dosing, with PEARL testing 5 mg and 10 mg once per week. There is no approved or established anti-aging dose, and the main pro-rapamycin opinion literature argues the dose must be individually titrated to the point where side effects appear rather than set to a fixed daily amount. It is a prescription drug, so any regimen should be set with a physician.

No trial has compared time of day, so an optimal hour is not established. What matters more is the interval: longevity regimens dose once weekly rather than daily, and it should be taken consistently with respect to food and never with grapefruit or grapefruit juice, which raises blood levels. Beyond avoiding those interactions, timing has not been directly optimized in humans.

At immunosuppressive doses the most common effects are mouth ulcers/stomatitis (reported in 20% or more), diarrhea and abdominal pain, elevated cholesterol (about 43 to 46%) and triglycerides (about 45 to 57%), edema, low blood counts, and acneiform rash, with serious risks including infection, impaired wound healing, and increased lymphoma and skin cancer. At the low weekly doses used for longevity in the PEARL trial, overall adverse events were similar to placebo, with gastrointestinal symptoms and mouth ulcers the most frequently reported.

Yes, extensively. Sirolimus is a CYP3A4 and P-glycoprotein substrate, so strong inhibitors such as ketoconazole, voriconazole, itraconazole, clarithromycin, erythromycin, and telithromycin can raise levels and toxicity, while strong inducers such as rifampin, rifabutin, and St. John's wort can lower it below effect. Live vaccines (for example MMR, varicella, yellow fever) should be avoided during use, and combining it with other immunosuppressants adds to infection risk.

Rapamycin (sirolimus) is a prescription immunosuppressant approved to prevent organ-transplant rejection; its use for longevity is experimental, off-label, and has not been shown to extend human lifespan. It is inappropriate for anyone who is pregnant, has an active infection, or faces upcoming surgery or wound healing, and it should only be considered by informed adults working with a physician who can monitor labs. It is not suited to self-directed use as a supplement.

There is no established timeframe because no human trial has demonstrated an anti-aging or lifespan endpoint for rapamycin. In the PEARL trial of intermittent weekly rapamycin, the statistically significant changes seen in women (lean tissue mass, self-reported pain) emerged over 24 to 48 weeks. A separate elderly trial of the rapamycin analog everolimus (RAD001) improved influenza-vaccine response by roughly 20% after a short dosing course, but that surrogate immune outcome is not the same as a longevity benefit.

Longevity protocols deliberately avoid daily dosing; they use low intermittent (typically once-weekly) doses precisely to limit the immunosuppression seen with continuous transplant-level dosing, which causes mouth ulcers, elevated lipids, impaired wound healing, higher infection risk, and increased lymphoma and skin-cancer risk. The longest healthy-aging study, PEARL, gave 5 or 10 mg weekly for 48 weeks and found adverse events similar to placebo. Safety of any regimen beyond about one year in healthy people has not been established, so this is not a self-directed long-term supplement.

Yes. Rapamycin (sirolimus) is a potent prescription immunosuppressant, and higher or continuous dosing increases stomatitis, hyperlipidemia, low blood counts, and infection risk. There is no dietary-supplement upper limit; longevity trials such as PEARL capped exposure at 5 to 10 mg once weekly, and clinical use is guided by a prescriber and often by blood-level monitoring rather than by a fixed ceiling.

The main concern is not synergy but interference with rapamycin's blood levels through the CYP3A4 and P-glycoprotein pathways. Grapefruit inhibits CYP3A4 and must not be taken with sirolimus, while St. John's wort induces CYP3A4 and can lower rapamycin to ineffective levels. Because it is a narrow-therapeutic-index drug, any supplement combination should be cleared with the prescribing physician rather than self-managed.

Rapamycin is not a dietary supplement; it is the prescription drug sirolimus (brand Rapamune) and legally requires a prescription, so any product sold over the counter as a "rapamycin supplement" is not legitimate. Longevity use relies on generic or compounded sirolimus obtained through a physician. Note that compounded rapamycin is not equivalent to commercial tablets: in the PEARL trial it produced roughly one-third the blood concentration at 24 hours, so source and formulation materially affect the dose actually delivered.